查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球注射式给药市场 - 2023-2030年
市场调查报告书
商品编码
1297776

全球注射式给药市场 - 2023-2030年

Global Injectable Drug Delivery Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球注射式给药市场在2022年达到6073亿美元，预计到2030年将见证有利可图的增长，达到13641亿美元。在2023-2030年的预测期间，注射给药市场预计将呈现出10.9%的年增长率。

在某些提醒、设备的自我使用、智能手机的连接和其他方面的帮助下，不断创新以改善患者在注射给药期间的体验。此外，目前的自我注射设备，包括笔和无针注射器，已经使注射给药变得相对容易。

注射剂是指通过注射配入人体的任何药物。越来越多的注射剂产品的开发和批准，以及其他因素，正在推动全球注射给药市场在预测期间的增长。

市场动态

越来越多的市场发展推动了预测期内全球注射式给药市场的增长

越来越多的市场发展，如产品引进、产品批准、收购、合作、合併、扩张和投资等等，正在推动预测期内全球注射给药市场的增长。

例如，2022年2月，日本跨国制药公司武田取得了美国FDA对其TAKHZYRO（Lanadelumab-flyo）注射液单剂量预填充注射器（PFS）的授权，用于避免成人和儿童患者（12岁及以上）的遗传性血管性水肿（HAE）的发作。

不断增长的老年人口为全球注射给药市场提供了前景广阔的增长机会

肠外给药被广泛用于老年病人，以达到和维持治疗指数较窄或口服生物利用度较差的药物的治疗浓度。因此，不断增长的老年人口为全球市场提供了未来几年的增长机会。

例如，根据联合国发布的《2022年世界人口前景》，80岁或以上的人的数量预计将增长三倍，从2022年的1.57亿增加到2050年的4.59亿。

COVID-19影响分析

COVID-19分析包括COVID前情景、COVID情景和COVID后情景以及定价动态（包括大流行期间和之后的定价变化与COVID前情景的比较）、需求-供应谱（由于贸易限制、封锁和后续问题造成的需求和供应的转变）、政府倡议（政府机构为振兴市场、部门或行业而采取的倡议）和制造商战略倡议（这里将涉及制造商为缓解COVID问题所采取的措施）。

俄乌战争影响分析

自俄罗斯入侵乌克兰以来，俄乌战争对市场产生了负面影响，292次攻击破坏或摧毁了218家医院和诊所，超过65次攻击救护车，181次攻击其他卫生基础设施，如血液中心、牙科诊所和药店。

全球经济衰退影响分析

在全球范围内，不断攀升的通货膨胀对全球注射给药市场产生了相当大的影响。大多数制药公司都在观察原材料价格的上涨，并预计利润率会下降。

医疗保健市场在非专利药和处方药的定价方面受到很大控制。然而，制药公司在药品定价方面正遇到越来越大的压力。这种日益增长的定价压力的主要原因是通货膨胀率的上升对全球市场增长产生了负面影响。

人工智能影响分析

由于产品的不断开发，人工智能正在对全球注射给药市场产生积极影响。例如，一组研究人员利用谷歌的人工智能企业DeepMind设计了一个细菌注射系统，可以将蛋白质，如杀癌药物和基因治疗，直接注入人体细胞。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品类型分析
  • 按包装分类
  • 按治疗应用分类
  • 按给药途径分类
  • 按分销渠道分类
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 产品进步
      • 市场发展
    • 限制因素
      • 针刺伤害
      • 替代给药系统的使用越来越多
    • 机会
    • 政府倡议
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19及未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：全球经济衰退分析

第九章：人工智能影响分析

第十章：按产品类型

  • 设备
    • 传统的注射设备
    • 自我注射装置
    • 自动注射器
    • 笔式注射器
    • 可穿戴注射器
    • 其他设备
  • 配方
    • 传统的给药配方
      • 溶液
      • 重组/冻干制剂
      • 悬浮液
      • 乳液
    • 新型药物制剂
      • 新生物体
      • 脂质体
      • 聚合物/混合细胞
      • 微粒子

第十一章：按包装分类

  • 小瓶
  • 安瓿
  • 瓶装
  • 盒装
  • 其他包装

第十二章：按治疗应用分类

  • 自身免疫性疾病
  • 激素性疾病
  • 孤儿病
  • 癌症
  • 其他治疗性疾病

第13章 ：按给药途径

  • 皮内注射
  • 中枢神经系统
  • 其他途径

第十四章：按销售渠道分类

  • 网上药店
  • 零售药店
  • 医院药店
  • 其他

第十五章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 俄罗斯
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第16章 ：竞争格局

  • 竞争格局
  • 市场份额分析
  • 合併和收购分析

第十七章 ：公司简介

  • Becton Dickinson & Company
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Baxter International, Inc.
  • Gerresheimer AG
  • Pfizer, Inc.
  • Schott AG
  • ELI Lilly and Company
  • Sandoz (A Division of Novartis AG)
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Corning Incorporated

第18章 ：附录

简介目录
Product Code: MD799

Market Overview

The Global Injectable Drug Delivery Market reached USD 607.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1,364.1 billion by 2030. The injectable drug delivery market is expected to exhibit a cagr of 10.9% during the forecast period 2023-2030.

Continuous innovations are subjected to improve patients' experience during injectable drug delivery with the help of certain reminders, the self-use of devices, connectivity of smartphones, and others. Moreover, the current self-injection devices, including pen and needle-free injectors, have made injectable drug delivery comparatively easier.

An injectable is any medication dispensed into the body via injections. The increasing number of injectable product development and approvals, among other factors, are driving the growth of the Global Injectable Drug Delivery Market during the forecast period.

Market Dynamics

The Increasing Number of Market Developments is Driving the Global Injectable Drug Delivery Market Growth in the Forecast Period

The increasing market developments, such as product introductions, product approvals, acquisitions, collaborations, mergers, expansion, and investments, among others, are driving the growth of the global injectable drug delivery market during the forecast period.

For instance, in February 2022, Takeda, a Japanese multinational pharmaceutical corporation, acquired US FDA authorization for its TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) utilized to avert episodes of hereditary angioedema (HAE) in adult and pediatric patients (12 years and above).

The Growing Geriatric Population is Providing the Global Injectable Drug Delivery Market with Prospective Growth Opportunities

Parenteral drug delivery is vastly utilized for geriatrics to attain and sustain a therapeutic concentration of medications with a narrow therapeutic index or poor oral bioavailability. Thus, the growing geriatric population presents the global market with future growth opportunities in the upcoming years.

For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

The Russia-Ukraine war has had a negative influence on the market since the Russian invasion of Ukraine with 292 attacks has damaged or destroyed 218 hospitals and clinics, over 65 attacks on ambulances, and 181 attacks on other health infrastructure, like blood centers, dental clinics, and pharmacies.

Global Recession Impact Analysis

All over the globe, climbing inflation is considerably impacting the Global Injectable Drug Delivery Market. Most pharmaceutical corporations are observing elevated prices for raw materials and are anticipating a reduction in profit margins.

The healthcare market is significantly controlled when it arrives to the pricing of generic and prescription medicines. Nevertheless, pharma corporations are encountering growing stress on drug pricing. The primary cause for this growing pricing strain is the elevated rate of inflation negatively impacting global market growth.

Artificial Intelligence Impact Analysis

Artificial intelligence is having a positive impact on the global injectable drug delivery market owing to increasing product developments. For instance, a group of investigators has harnessed Google`s AI venture DeepMind to design a bacterial injection system that can inject proteins, such as cancer-killing medicines and gene treatments, directly into human cells.

Segment Analysis

The Global Injectable Drug Delivery Market is segmented based on product type, packaging, therapeutic application, route of administration, distribution channel, and region.

The Hormonal Therapeutic Application Segment is Estimated to Hold highest Share of the Global Market.

Owing to the increasing product approvals for hormonal disorders and growing cases of hormonal disorders the hormonal therapeutic application segment is estimated to hold 30.9% of the global injectable drug delivery market.

For instance, in July 2022, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a favorable view and suggested consent for the usage of Mounjaro (tirzepatide) auto-injector pen for type 2 diabetes. Moreover, the 2022 National Diabetes Statistics Report by CDC estimated that over 130 million adults with diabetes or prediabetes in the United States.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Injectable Drug Delivery Market During the Forecast Period

Owing to the increasing product approvals in Europe, the region is estimated to be around 29.6% of the global injectable drug delivery market by 2030.

For instance, in February 2021, Xeris Pharmaceuticals acquired authorization from the European Commission (EC) for its Ogluo (glucagon) pre-filled pen indicated for treating extreme hypoglycemia in children, adults, and adolescents aged 2 years and over with diabetes mellitus.

Competitive Landscape

The major global players in the market include: Becton Dickinson & Company, Baxter International, Inc., Gerresheimer AG, Pfizer, Inc., Schott AG, Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceutical Industries Ltd, Corning Incorporated, among others.

Why Purchase the Report?

  • To visualize the Global Injectable Drug Delivery Market segmentation based on product type, packaging, therapeutic application, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous injectable drug delivery market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Injectable Drug Delivery Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Packaging
  • 3.3. Snippet by Therapeutic Application
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Product Advancements
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Needle Stick injuries
      • 4.1.2.2. The Increasing Use of Alternative Drug Delivery Systems
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Product Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.1.2. Market Attractiveness Index, By Product Type
  • 10.2. Devices
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Conventional injection devices
    • 10.2.4. Self-injection devices
    • 10.2.5. Autoinjectors
    • 10.2.6. Pen Injectors
    • 10.2.7. Wearable injectors
    • 10.2.8. Other devices
  • 10.3. Formulations
    • 10.3.1. Conventional drug delivery formulation
      • 10.3.1.1. Solutions
      • 10.3.1.2. Reconstituted/Lyophilized Formulations
      • 10.3.1.3. Suspensions
      • 10.3.1.4. Emulsions
    • 10.3.2. Novel drug formulations
      • 10.3.2.1. Niosomes
      • 10.3.2.2. Liposomes
      • 10.3.2.3. Polymeric/mixed cells
      • 10.3.2.4. Microparticles

11. By Packaging

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 11.1.2. Market Attractiveness Index, By Packaging
  • 11.2. Vials*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Ampule
  • 11.4. Bottle
  • 11.5. Cartridges
  • 11.6. Others

12. By Therapeutic Application

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 12.1.2. Market Attractiveness Index, By Therapeutic Application
  • 12.2. Autoimmune Disease
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hormonal Disorders
  • 12.4. Orphan disease
  • 12.5. Cancer
  • 12.6. Other therapeutic diseases

13. By Route of Administration

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.1.2. Market Attractiveness Index, By Route of Administration
  • 13.2. Intradermal
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Central Nervous System
  • 13.4. Others

14. By Distribution Channel

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.1.2. Market Attractiveness Index, By Distribution Channel
  • 14.2. Online Pharmacies
    • 14.2.1. Introduction
    • 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 14.3. Retail pharmacies
  • 14.4. Hospital Pharmacies
  • 14.5. Others

15. By Region

  • 15.1. Introduction
    • 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 15.1.2. Market Attractiveness Index, By Region
  • 15.2. North America
    • 15.2.1. Introduction
    • 15.2.2. Key Region-Specific Dynamics
    • 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.2.8.1. The U.S.
      • 15.2.8.2. Canada
      • 15.2.8.3. Mexico
  • 15.3. Europe
    • 15.3.1. Introduction
    • 15.3.2. Key Region-Specific Dynamics
    • 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.3.8.1. Germany
      • 15.3.8.2. The U.K.
      • 15.3.8.3. France
      • 15.3.8.4. Italy
      • 15.3.8.5. Russia
      • 15.3.8.6. Rest of Europe
  • 15.4. South America
    • 15.4.1. Introduction
    • 15.4.2. Key Region-Specific Dynamics
    • 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.4.8.1. Brazil
      • 15.4.8.2. Argentina
      • 15.4.8.3. Rest of South America
  • 15.5. Asia-Pacific
    • 15.5.1. Introduction
    • 15.5.2. Key Region-Specific Dynamics
    • 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.5.8.1. China
      • 15.5.8.2. India
      • 15.5.8.3. Japan
      • 15.5.8.4. Australia
      • 15.5.8.5. Rest of Asia-Pacific
  • 15.6. Middle East and Africa
    • 15.6.1. Introduction
    • 15.6.2. Key Region-Specific Dynamics
    • 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

16. Competitive Landscape

  • 16.1. Competitive Scenario
  • 16.2. Market Share Analysis
  • 16.3. Mergers and Acquisitions Analysis

17. Company Profiles

  • 17.1. Becton Dickinson & Company
    • 17.1.1. Company Overview
    • 17.1.2. Product Portfolio and Description
    • 17.1.3. Financial Overview
    • 17.1.4. Key Developments
  • 17.2. Baxter International, Inc.
  • 17.3. Gerresheimer AG
  • 17.4. Pfizer, Inc.
  • 17.5. Schott AG
  • 17.6. ELI Lilly and Company
  • 17.7. Sandoz (A Division of Novartis AG)
  • 17.8. Terumo Corporation
  • 17.9. Teva Pharmaceutical Industries Ltd.
  • 17.10. Corning Incorporated

LIST NOT EXHAUSTIVE

18. Appendix

  • 18.1. About Us and Services
  • 18.2. Contact Us